ADMA BIOLOGICS, INC. — Director's Dealing 2015

Mar 19, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ADMA BIOLOGICS, INC. (ADMA)
CIK: 0001368514
Period of Report: 2015-03-16

Reporting Person: Grossman Adam S (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-03-16	Common Stock, $0.0001 par value per share	P	8500	$8.0323	Acquired	618957	Indirect
2015-03-16	Common Stock, $0.0001 par value per share	P	300	$7.9766	Acquired	619257	Direct
2015-03-16	Common Stock, $0.0001 par value per share	P	100	$7.97	Acquired	619357	Indirect
2015-03-16	Common Stock, $0.0001 par value per share	P	100	$7.97	Acquired	619457	Indirect
2015-03-16	Common Stock, $0.0001 par value per share	P	100	$7.99	Acquired	619557	Indirect
2015-03-17	Common Stock, $0.0001 par value per share	P	5500	$7.9782	Acquired	625057	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.8399 to $8.10 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on March 16, 2015.

F2: 580,957 of these shares are held by Hariden, LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.

F3: 35,700 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.

F4: These shares are being purchased by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.

F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.95 to $7.9899 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on March 16, 2015.

F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.90 to $8.01 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on March 17, 2015.

F7: 41,200 of these shares are held by Areth LLC, an entity for which Adam Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.